Skip to main content
OpenTrials
Completed

NCT Number: NCT06899191

Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED

The goal of this clinical trial is to improve the processes of Type 2 Diabetes (T2D) care coordination and treatment in the emergency department (ED) by utilizing clinical decision support mechanisms in the electronic health record (EHR). The main question is whether electronic prompts triggered by hyperglycemia and elevated A1c results in providers providing earlier treatments and faster time to subsequent primary care appointment and greater reduction in hemoglobin A1c (HA1c).

ED clinicians will receive alerts called Our Practice Advisories (OPA's) through the EPIC EHR. The 1st OPA triggers when a random point-of-care (POC) glucose is ≥250 mg/dL, prompting a suggested additional HA1c order. A 2nd OPA triggers if the resulting HA1c is ≥10%, prompting consideration of further care coordination in the Observation Unit. Investigators will compare the outcomes post-intervention compared to pre-intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rutgers, Robert Wood Johnson Hospital

New Brunswick, New Jersey, 08901, United States

About this study

Type 2 Diabetes (T2D) is a growing public health crisis with rates of diabetes steadily increasing over the last 10 years. The ED is commonly the first point of contact for individuals who present with symptoms of hyperglycemia, often with very severe (HbA1C > 10%) underlying diabetes. However, there is currently no national guideline or clinical policy for the ED management of patients who are not in diabetic ketoacidosis (DKA) or in a hyperglycemia hyperosmolar state (HHS). The investigators hypothesize that there are two subgroups who may benefit from greater care coordination initiated from the ED: patients who are newly-diagnosed with severe T2D and patients whom T2D is poorly-controlled despite medication adherence. This study designs electronic prompt practice advisories that nudge ED providers towards more aggressive treatment pathways. It is currently unknown whether alert tools can improve the delivery and coordination of care of patients with severe T2D presenting to the ED.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Moderate hyperglycemia, (glucose ≥250 mg/dL)

  • Patients who arrive in the emergency department
  • Not pregnant or peri-partum
  • Not SARS-COV-2 PCR positive in past 7 days

Exclusion criteria

  • Diabetic ketoacidosis (pH < 7.20, HCO3 < 15, AG > 25)
  • Diabetic foot ulcer or skin complications
  • Hyperglycemic hyperosmolar state with neurologic impairment
  • Patients who leave against medical advice (AMA), elope from the ED, or are transferred to another facility

Treatment and study plan

Hemoglobin A1c

Diagnostic Test

Prompt to order A1c

Observation Unit

Behavioral

Electronic prompt nudging ED provider to consider admitting patient to the Observation Unit for care coordination and more aggressive glycemic control

Primary outcomes

  1. Care Coordination: Follow-Up Care

    Time frame: From date of ED encounter until 4 weeks after

    % Patients achieving: A T2D-related appointment within 4 weeks

  2. Physiologic Response

    Time frame: From date of ED encounter to 4 months after

    % Patients achieving: HbA1c 1% reduction in 3 months

Secondary outcomes

  1. Care Coordination: Disposition

    Time frame: Within 1 day of ED encounter date

    number of patients discharged, number of patients admitted to observation unit, number of patients admitted to hospital

  2. Care Coordination: Length of stay

    Time frame: 1 day

    Length of stay (minutes) of subject ED encounter

  3. Care Coordination: Insurance

    Time frame: Within 3 weeks of ED encounter

    Inclusion: patients with NO insurance Measure % Patients achieving new insurance

  4. Care Coordination: Medication Prescription

    Time frame: 3 days

    Inclusion: patients discharged from the ED or observation Unit

    % subjects prescribed a diabetes medication

  5. Care Coordination: Medication Change

    Time frame: 3 days

    Inclusion: patients discharged from the ED or observation Unit

    % subjects with a change in diabetes medication regimen

  6. Care Coordination: Appointment

    Time frame: 3 months

    Time (days) to next appointment related to T2D, calculated as [Appt date] - [ED encounter date]

  7. Physiologic: A1c Orders

    Time frame: 1 day

    Proportion of patients with hemoglobin A1c ordered in the ED

  8. Physiologic: Serum Glucose

    Time frame: 1 day

    Serum glucose concentration change from beginning to end of ED encounter

  9. Physiologic: Hemoglobin A1c percentage

    Time frame: 6 months

    Serum hemoglobin A1c (%)

  10. Physiologic: Diagnosis

    Time frame: 1 day

    Proportion of subjects with newly diagnosed Type 2 Diabetes, proportion of subjects with poorly controlled, established Type 2 Diabetes

  11. Physiologic: ED medications

    Time frame: 1 day

    % subjects receiving (1) intravenous fluids, (2) insulin, (3) other diabetes medications while in the ED

Sponsors and collaborators

Lead sponsor

Rutgers, The State University of New Jersey

Other

Registry information

Official study title

Diabetes Electronic Prompt for Improved Care Coordination and Treatment (DEPICCT) in the ED

Acronym: DEPICCT

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 27, 2025
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.